Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat-containing protein 19 (WDR19) is a member of the WD-repeat protein family, characterized by conserved repeating units of about 40 amino acids usually bracketed by WD dipeptides, which commonly fold into a beta-propeller structure[4][6]. WDR19 is a critical component of the intraflagellar transport complex A (IFT-A), required for the retrograde movement of materials within cilia and flagella[1][2][3]. Proper function of WDR19 ensures normal cilia formation and maintenance, which is essential for various signaling pathways (notably Sonic Hedgehog signaling), organ development (including kidney, retina, bone), and tissue patterning during embryogenesis[1][2][3]. Mutations in WDR19 disrupt cilia structure and function, causing a spectrum of rare inherited diseases known as ciliopathies, which include cranioectodermal dysplasia, nephronophthisis, retinitis pigmentosa, and other syndromic conditions involving renal, skeletal, and visual organ systems[1][2][3]. WDR19 is not therapeutically targeted by drugs, but pathogenic mutations in this gene are relevant for diagnostic genetics of these rare disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat-containing protein 19 (WDR19).